We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




High Liver Enzymes Increase Diabetes Risk for Hispanic Adults

By LabMedica International staff writers
Posted on 08 Apr 2021
Print article
Image: Elevated liver enzymes are associated with incident diabetes in US Hispanic/Latino adults (Photo courtesy of Judy George, BA, MBA)
Image: Elevated liver enzymes are associated with incident diabetes in US Hispanic/Latino adults (Photo courtesy of Judy George, BA, MBA)
Non‐alcoholic fatty liver disease (NAFLD) has been associated with increased risk of incident diabetes, but such evidence is lacking in the Hispanic/Latino population, which has high prevalence of obesity and NAFLD.

NAFLD, also known as metabolic (dysfunction) associated fatty liver disease (MAFLD), is excessive fat build-up in the liver without another clear cause such as alcohol use. There are two types; non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), with the latter also including liver inflammation.

Medical Scientists at the Albert Einstein College of Medicine (Bronx, NY, USA) analyzed data from 6,928 adults participating in the Hispanic Community Health Study/Study of Latinos (mean age, 38 years). Participants did not have diabetes at a baseline visit from 2008 to 2011 and returned for a follow-up examination a mean six years after baseline from 2014 to 2017. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase (GGT) levels were measured at baseline. The team placed participants into quartiles for ALT, AST and GGT based on their baseline levels. Incident diabetes was identified at follow-up through laboratory measurements or the use of diabetes medication.

The scientists reported that of the 738 participants who had diabetes during follow-up, 533 were identified through blood tests. Adults were more likely to develop diabetes if they were men, older or of Puerto Rican background or had a lower education level, higher BMI, higher waist circumference or a lower score on an alternative healthy eating index. adults in the highest ALT quartile had a greater risk for developing diabetes compared with those in the lowest quartile (Relative Risk [RR] = 1.51). Participants in the highest quartile for GGT also had an increased risk for diabetes at follow-up compared with the lowest quartile (RR = 2.39). Both associations remained after adjusting for baseline fasting glucose. After adjusting for homeostatic model assessment of insulin resistance, only a high GGT level was significantly associated with incident diabetes.

The risks for incident diabetes with ALT and GGT were similar for all Hispanic backgrounds except for Dominican ethnicity. ALT and GGT were both associated with incident diabetes regardless of obesity status. Those who had a high ALT and were light or moderate alcohol drinkers had an increased risk for incident diabetes (RR = 1.5), but there was no increased risk for those who did not drink. In addition to using liver enzyme testing to screen Hispanic adults for their diabetes risk, the findings revealed that lifestyle modifications can reduce a person’s risk for both NAFLD and diabetes.

Carmen R. Isasi, MD, PhD, FAHA, an associate professor and the senior author of the study, said, “Hispanics are at high risk of diabetes and its complications and are also at high risk for nonalcoholic fatty liver disease (NAFLD). Liver enzymes could be a simple clinical tool to screen individuals for diabetes risk, in addition to traditional factors.”
The authors concluded that higher ALT and GGT levels are associated with increased risk of developing diabetes among Latinos. Liver enzyme tests might aid in diabetes prevention by identifying high‐risk individuals. The study was originally published online on January 21, 2021 in the journal Diabetic Medicine.

Related Links:
Albert Einstein College of Medicine

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.